<DOC>
	<DOCNO>NCT00172029</DOCNO>
	<brief_summary>The aim prospective , randomize , open-label , multicentric clinical study ass effícacy tolerability zoledronic acid 4 mg IV infuse 15 minute every 4 week total 6 infusion , combination standard reduce dose radiotherapy patient breast cancer metastatic bone disease associate pain .</brief_summary>
	<brief_title>Study Comparing Full-dose Radiotherapy Versus Reduced Dose Management Bone Metastasis Patients With Breast Cancer Receiving Zoledronic Acid</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Bone Diseases</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Female patient age ≥ 18 year . Histologically confirm diagnosis breast cancer least one bone metastases . Radiologically documented solitary multiple osteolytic osteoblastic lesion axial skeleton extremity radiotherapy indicate . Pain and/or analgesic score ≥ 3 ( see section 3.5.2 ) bone site irradiate . ECOG performance status ≤ 2 . Life expectancy 6 month . Patients target lesion ( ) detectable conventional technique ( i.e . Xrays MRI CT scan ) . Presence pathological fracture target lesion ( ) . Prior irradiation painful area ( ) irradiate . Known hypersensitivity zoledronic acid biphosphonates . Previous treatment bisphosphonates current disease ; treatment biphosphonates indication anyway discontinue least two year randomization study . Skeletonrelated complication ( e.g. , pathological fracture , orthopedic intervention treat stabilize osteolytic defect , spinal cord compression ) last 3 week prior first infusion trial medication . Change anticancer therapy within 2 week prior screen assessment and/or test treatment start . Patients severe renal function ( serum creatinine &gt; 400 umol/l &gt; 4.5 mg/dl calculate creatinine clearance ≤ 30 ml/minute ) prior renal transplantation . Creatinine clearance calculate use follow formula : Creatinine clearance = ( 140age [ yr ] ) ( body weight [ kg ] ) x 0.85 ( 72 ) ( serum creatinine [ mg/dL ] ) Creatinine clearance = ( 140age [ yr ] ) ( body weight [ kg ] ) x 0.85 ( 0.814 ) ( serum creatinine [ µmol/L ] ) Corrected ( adjust serum albumin ) serum calcium concentration &lt; 8.0 mg/dl ( 2.00 mmol/L ) . Patients clinically symptomatic brain metastasis Bone metabolism disorder , e.g . Paget disease , primary hyperparathyroidism Serious intercurrent illness breast cancer interfere evaluation effect therapy . Pregnancy lactation . Women childbearing potential effective form contraception . Known history present abuse alcohol drug ( accept social alcohol usage exclude patient ) Patients , opinion investigator , unlikely cooperate fully study . Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>Zoledronic acid</keyword>
	<keyword>Radiotherapy</keyword>
	<keyword>Bone pain</keyword>
	<keyword>Breast cancer</keyword>
</DOC>